Subscribe To
DBTX / Decibel Therapeutics to Participate in Upcoming Investor Conferences
DBTX News
By Seeking Alpha
September 15, 2023
Decibel Therapeutics' CVR Appears Around Fair Value
Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hear more_horizontal
By Investopedia
August 9, 2023
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene th more_horizontal
By InvestorPlace
August 9, 2023
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This de more_horizontal
By Proactive Investors
August 9, 2023
Decibel Therapeutics shoots up 72% on Regeneron bid
Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be more_horizontal
By Market Watch
August 9, 2023
Regeneron buying small cap Decibel Therapeutics for $4 a share
Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its more_horizontal
By Benzinga
June 28, 2022
Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study
Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-02 more_horizontal
By GlobeNewsWire
March 22, 2022
Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and de more_horizontal